INtravenous Contrast computed tomography versus native computed tomography in patients with acute Abdomen and impaired Renal functiOn (INCARO) : a multicentre, open-label, randomised controlled trial - study protocol by Raty, Panu et al.
1Räty P, et al. BMJ Open 2020;10:e037928. doi:10.1136/bmjopen-2020-037928
Open access 
INtravenous Contrast computed 
tomography versus native computed 
tomography in patients with acute 
Abdomen and impaired Renal functiOn 
(INCARO): a multicentre, open- label, 
randomised controlled trial - 
study protocol
Panu Räty   ,1 Panu Mentula,1 Hanna Lampela,1 Taina Nykänen,2 Ilkka Helanterä,3 
Mikko Haapio,4 Tiina Lehtimäki,5 Markus B Skrifvars,6 Suvi T Vaara,7 
Ari Leppäniemi,1 Ville Sallinen1,3
To cite: Räty P, Mentula P, 
Lampela H, et al.  INtravenous 
Contrast computed tomography 
versus native computed 
tomography in patients with 
acute Abdomen and impaired 
Renal functiOn (INCARO): 
a multicentre, open- label, 
randomised controlled trial 
- study protocol. BMJ Open 
2020;10:e037928. doi:10.1136/
bmjopen-2020-037928
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
037928).
Received 24 February 2020
Revised 30 June 2020
Accepted 14 August 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Ville Sallinen;  
 ville. sallinen@ helsinki. fi
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction CT is the primary imaging option for acute 
abdominal pain in adults. Intravenous (IV) contrast media 
use improves CT quality but may cause post- contrast 
acute kidney injury (PC- AKI). Retrospective studies show 
no association between reduced baseline renal function 
and IV contrast CT, but, to our knowledge, no data from 
randomised controlled trials exist.
Methods and analysis The INCARO (INtravenous Contrast 
computed tomography versus native computed tomography 
in patients with acute Abdomen and impaired Renal functiOn) 
trial is a multicentre, open- label, parallel group, superiority, 
individually randomised controlled trial comparing IV 
contrast- enhanced CT to native CT in patients requiring 
emergency abdominal or body CT with impaired renal 
function defined as an estimated glomerular filtration rate 
(eGFR) of 15 to 45 mL/min/1.73 m2. The primary outcome 
is a composite of all- cause mortality or renal replacement 
therapy (RRT) within 90 days from CT. Secondary outcomes 
are AKI measured by KDIGO (The Kidney Disease: Improving 
Global Outcomes) criteria within 72 hours from CT, organ 
dysfunction defined by mSOFA (modified Sequential Organ 
Failure Assessment) criteria after 48 hours from CT, alive 
and hospital- free days within 90 days after CT, and time 
from imaging to definitive treatment. All- cause mortality, 
need for RRT and renal transplant in long- term follow- up are 
also measured. The calculated sample size is 994 patients. 
Patient recruitment is estimated to take 3 years.
Ethics and dissemination The Ethics Committee of 
Helsinki University Hospital approved the study. The 
findings will be disseminated in peer- reviewed academic 
journals.
Trial registration number NCT04196244
INTRODUCTION
The primary imaging option for the radio-
logical diagnosis of acute abdominal pain in 
adults is CT. CT imaging commonly utilises 
iodinated intravenous contrast media that 
improve image quality. In most abdominal 
pathologies, intravenous contrast media 
enable more accurate imaging and increase 
the sensitivity and specificity of radiological 
diagnosis. Contrast media enhance the visu-
alisation of various tissues. Contrast adminis-
tration enables the detection of lesions from 
normal surrounding structures and the diag-
nosis of parenchymal and vascular pathol-
ogies. When diagnosing acute abdomen, 
contrast- enhanced CT is the gold standard 
Strengths and limitations of this study
 ► To our knowledge, the INCARO (INtravenous Contrast 
computed tomography versus native computed to-
mography in patients with acute Abdomen and im-
paired Renal functiOn) trial is the first randomised 
controlled trial examining the diagnostic strategy of 
acute abdomen using intravenous (IV) contrast CT 
versus native CT in a growing population of patients 
with impaired renal function.
 ► The prospective study setting and randomisation 
will minimise the selection bias associated with 
previous retrospective studies, and multicentre tri-
al permits the formation of larger and more reliable 
patient cohort.
 ► Due to comprehensive registry data, it is possible to 
evaluate long- term effects of IV contrast exposure.
 ► As in the former studies, kidney injury evaluation is 
mainly based on estimated glomerular filtration rate 
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and, in most conditions, even mandatory for correct 
diagnosis. However, post- contrast acute kidney injury 
(PC- AKI), especially in patients with pre- existing renal 
insufficiency, has remained a significant concern among 
physicians for more than 60 years.1 2 Earlier, the most 
common definition of PC- AKI was the increase of serum 
creatinine level to more than 44 umol/L or by 25% in 48 
to 72 hours after contrast medium administration. Today, 
literature recommends KDIGO (The Kidney Disease: 
Improving Global Outcomes) criteria.3 The pathophysi-
ology of PC- AKI is complex and still poorly understood. 
According to present hypothesis, it is mediated by renal 
medullary hypoxia and direct cellular damage. Presence 
of endothelial dysfunction, for example, in diabetes 
mellitus, can further worsen these effects.4
A vast amount of early literature supports the existence 
of PC- AKI as a true clinical phenomenon. However, these 
studies are mostly retrospective, lack control groups and 
study intra- arterial instead of IV contrast administration.5 
In addition, modern iso- osmolality and low- osmolality 
contrast media are associated with lower risk of kidney 
injury than older high- osmolality contrast media.6 
Furthermore, the diagnosis of PC- AKI was typically based 
on the increase of serum creatinine level, although this 
increase seems equally common in patients not receiving 
intravenous contrast medium.7
More recent studies compare the incidence of PC- AKI 
in non- randomised designs between cohorts receiving 
contrast CT and native CT. In a recent meta- analysis, 
including 28 original articles and 107 335 patients, the 
incidence of PC- AKI varied between 2.1% and 26.4%. 
The meta- analysis did not show any differences between 
contrast- enhanced CT and native CT in AKI, mortality 
or dialysis rates.8 Another recent meta- analysis studied 
13 non- randomised studies with control groups repre-
senting 25 950 patients. Again, no differences between 
the contrast and non- contrast groups were detectable in 
AKI, mortality or dialysis rates. The result was similar even 
in patients with diabetes or chronic renal insufficiency.5 
Limitations of the findings include the retrospective and 
non- randomised nature of the studies leading to a risk 
of selection bias, non- standardised definitions of PC- AKI 
across the studies and lack of documentation of preventive 
actions such as pre- imaging and post- imaging hydration.
To decrease the selection bias, the newer studies use 
propensity score matching. A study with 12 508 propensity 
score- matched patients showed an association between 
diminished baseline estimated glomerular filtration rate 
(eGFR) and elevated post- imaging creatinine level diag-
nosed as AKI. However, the risk of AKI was independent 
of contrast administration, even in patients with eGFR 
below 30 mL/min/1.73 m2.9 Another propensity score- 
matched study with 20 242 patients showed an associ-
ation of low- osmolality iodinated intravenous contrast 
and AKI in patients with eGFR below 30 mL/min/1.73 
m2. Patients with eGFR between 30 and 44 mL/min/1.73 
m2 showed a similar but not statistically significant trend. 
In patients with eGFR of over 45 mL/min/1.73 m2, the 
contrast media appeared not to be nephrotoxic.10 A 
recent propensity score- matched study from an emer-
gency department with 17 934 patients showed no associa-
tion between contrast media administration and AKI, not 
even with the lowest eGFR levels below 30 mL/min/1.73 
m2. In addition, the study did not show any association 
between contrast media administration and the inci-
dence of chronic kidney disease, dialysis or renal trans-
plantation at 6 months.11
Studies on PC- AKI in various patient populations exist: 
a recent study on the incidence of PC- AKI in patients 
with nephrotic syndrome found no association between 
contrast administration and AKI in any eGFR subgroup.12 
A retrospective study on trauma patients over 55 years of 
age found no difference between intravenous contrast 
and native CT in terms of PC- AKI.13 A recent propensity 
score- matched study examined an intensive care unit 
(ICU) population of 6877 patients undergoing abdom-
inal, pelvic or chest CT examination. Patients with pre- CT 
eGFR above 45 mL/min/1.73 m2 showed no increase in 
PC- AKI, emergency dialysis or short- term mortality rates. 
However, patients with eGFR equal or below 45 mL/
min/1.73 m2 needed dialysis more often but no differ-
ences in post- CT AKI or 30- day mortality rates were seen.14
To summarise, a large amount of literature on PC- AKI 
exists, most of it retrospective and observational. The 
studies vary in definition of AKI and selection bias, which 
is a significant concern. In addition, retrospective study 
designs do not allow controlling for pre- scan and post- 
scan preventive actions, such as oral or IV hydration. Most 
studies show no association between intravenous contrast 
administration during CT examination and AKI, dialysis 
or mortality in any eGFR subgroups. However, the results 
vary in patients with eGFR below 45 mL/min/1.73 m2. 
Earlier studies are summarised in online supplemental 
file.
The extensive use of CT imaging, the superiority of 
contrast- enhanced CT over native CT and the growing 
population of patients with compromised renal function 
set a tremendous need for a randomised controlled trial 
studying the safety of intravenous contrast administration 
during CT imaging in patients with impaired renal func-
tion. To the best of our knowledge, this would be the first 
randomised controlled trial on this subject.
Our research hypothesis is that IV contrast admin-
istration does not cause increased mortality or any 
organ failure in patients with compromised renal func-
tion (eGFR 15 to 45 mL/min/1.73 m2) undergoing CT 
imaging for acute abdomen. By enhancing the diagnostic 
value of CT imaging, intravenous contrast administration 
could shorten the time to diagnosis and definitive treat-
ment and, thus, improve patients’ prognosis.
METHODS AND ANALYSIS
Study design
The INCARO (INtravenous Contrast computed tomog-
raphy versus native computed tomography in patients 
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with acute Abdomen and impaired Renal functiOn) trial 
is a randomised prospective multicentre, open- label study 
recruiting in university and central hospitals in Finland. 
Participating hospitals are Helsinki University Hospitals 
Meilahti and Jorvi, and Hyvinkää Hospital. More hospitals 
may be added after the commencement of the trial. The 
trial is registered at  ClinicalTrials. gov (NCT04196244). All 
participants will give written informed consent. Patient 
enrolment will be performed by all treating physicians. 
Most patients will be enrolled from hospitals’ emergency 
departments, surgical wards and ICUs.
Inclusion criteria
Patients requiring emergency abdominal or body CT with 
eGFR 15 to 45 mL/min/1.73 m2 will be screened for eligi-
bility for this study. The eGFR is calculated from the last 
available plasma creatinine value taken a maximum 24 
hours before randomisation.
Exclusion criteria
The exclusion criteria are: (1) age less than 18 years, (2) 
eGFR less than 15 or more than 45 mL/min/1.73 m2, (3) 
renal replacement therapy (RRT) within 30 days prior 
enrolment, (4) CT with intravenous contrast less than 72 
hours prior enrolment, (5) suspicion of vascular occlu-
sion, dissection or bleeding (ie, need for IV contrast), 
(6) CT needed without IV contrast to detect or rule out 
ureteral stone, (7) intravenous contrast allergy, (8) preg-
nancy, and (9) no signed written informed consent.
Trial interventions
Intervention groups are:
1. abdominal or body CT with IV contrast, and
2. abdominal or body CT without intravenous contrast 
(native CT).
Both groups receive intravenous hydration with at least 
3 mL/kg (equals 240 mL in 80 kg patient) of Ringer’s 
lactate or 0.9% NaCl before and after contrast medium 
exposure. The pre- CT intravenous hydration is recom-
mended to be infused over 3 hours and post- CT intrave-
nous hydration over 4 to 6 hours. However, intravenous 
hydration may not postpone the CT scan if the treating 
physician deems CT necessary sooner. Laboratory tests 
are obtained before intervention and on post CT days 1, 
2 and 3. If patients are discharged before 72 hours from 
the CT scan, they will be scheduled for a laboratory creati-
nine control on the third day after the CT scan. Figure 1 
summarises the study flow.
Otherwise, the treatment of the patients is according 
to normal standard care in both groups. For example, 
the decision to admit patient to ICU or commence RRT 
are made according to each participating hospital’s stan-
dard operating protocol. Repeat CT scans are allowed 
if deemed necessary by treating physician or surgeon, 
Figure 1 Flowchart of the INCARO trial. AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; INCARO, 
INtravenous Contrast computed tomography versus native computed tomography in patients with acute Abdomen and 
impaired Renal functiOn; IV, intravenous; KDIGO, The Kidney Disease: Improving Global Outcomes; mSOFA; modified 
sequential organ failure assessment; RRT, renal replacement therapy.
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and these will be taken in account while analysing the 
outcomes.
Iodinated contrast media are administered according 
to hospital guidelines. The type and amount of contrast 
medium is recorded. Study hospitals normally use low- 
osmolality iodinated intravenous contrast medium 
(concentration 350 mgI/mL) for urgent and non- urgent 
abdominal and body CT. The amount of contrast medium 
is 1.5 mL/kg.
Randomisation
Patients will be randomised 1:1 to undergo either intrave-
nous contrast CT or native CT. Randomisation sequence 
will be generated using a computer software with vari-
able block size (4, 6 and 8) and will be concealed from 
recruiters, attending physicians, patients, data collectors 
and data analysts. Randomisation will be done using web- 
based computer system. Randomisation sequence will be 
stratified for:
 ► eGFR 15 to <30 vs 30 to 45 mL/min/1.73 m2
 ► Patient age <65 vs 65 years or over
 ► Centre
As the attending physicians need to be able to analyse 
the CT images, the study is open- label. After a patient 
gives written informed consent, the attending physician 
performs randomisation and orders a CT scan.
Outcomes
The primary outcome is a composite that combines 
all- cause mortality and RRT within 90 days of CT. The 
secondary outcomes are: (1) the most severe AKI 
stage defined by the KDIGO plasma creatinine criteria 
(table 1)15 within 72 hours after CT, (2) any organ 
dysfunction defined by at least two organ- specific mSOFA 
(modified SOFA) points (table 2) excluding central 
nervous system 48 hours after CT, (3) alive and hospital- 
free days within 90 days after CT and (4) time from CT 
to definitive treatment (ie, surgery, radiological inter-
vention, endoscopy or medication) during hospital stay. 
Tertiary outcomes are all- cause mortality, RRT and renal 
transplant at 6 months, 1, 5 and 10 years after CT.
Sample size calculation
A previous study conducted at the Helsinki University 
Hospital on patients with diffuse peritonitis showed a 
90- day overall mortality of 22%. In patients with eGFR 
less than 45 mL/min/1.73 m2, the mortality was 39%. 
Patients with any perforation of the gastrointestinal (GI) 
tract had an overall mortality of 13%, whereas patients 
with eGFR less than 45 mL/min/1.73 m2 had a mortality 
of 25%.16 The documented incidence of AKI in hospital-
ised patients is 1.9%, and in ICU patients, the incidence 
exceeds 40%.17 A recent meta- analysis of post- CT AKI 
showed an incidence of AKI of 7.17% in contrast CT 
group and 7.42% in native CT group. In contrast and 
non- contrast groups, RRT was necessary in 0.56% and 
0.68% of patients, respectively.8 The incidence of AKI 
after major abdominal surgery is 13.4% and rates of post-
operative RRT vary from 0% to 3% between studies.18 
After general surgery procedure, the incidence of AKI is 
1%, and the post- surgery RRT rate is 0.68%.19 Risk factors 
for postoperative AKI include emergency surgery, intra-
peritoneal surgery, and mild or moderate renal insuffi-
ciency,19 all leading to a higher than 1% rate of AKI and 
RRT.
All patients included in this trial will not have a GI tract 
perforation. Some patients might not have abdominal 
pathology, although it was suspected when ordering the 
CT scan. Thus, the mortality rate in the trial cohort will 
likely be lower than 25%. On the other hand, a composite 
outcome comprising all- cause mortality, RRT and renal 
transplantation will likely increase the rate of the primary 
outcome. We estimate that the primary outcome rate is 
27% in the native CT group and 9 percentage points less 
(ie, 18%) in the intravenous contrast CT group. With 
Table 1 KDIGO classification stages for AKI based on 
creatinine level
Stage Creatinine
1 1.5 to 1.9 times baseline or ≥26.5 μmol/L 
(≥0.3 mg/dL) increase
2 2.0 to 2.9 times baseline
3 3.0 times baseline or increase in serum 
creatinine to ≥353.6 μmol/L (≥4.0 mg/dL) or 
initiation of renal replacement therapy
AKI, acute kidney injury; KDIGO, The Kidney Disease: Improving 
Global Outcomes.
Table 2 Modified SOFA score
0 1 2 3 4
Respiration No support Supplemental 
oxygen
NIV Invasive ventilation
Coagulation (platelets; ×103/mm3) ≥150 <150 <100 <50 <20
Liver (bilirubin; μmol/L) <20 20 to 32 33 to 101 102 to 204 >204
Cardiovascular MAP ≥70 mm Hg MAP <70 mm Hg Vasoactive drugs used
Renal function (creatinine μmol/L) <110 110 to 170 171 to 299 300 to 440 >440 or RRT
GCS (Glasgow coma scale) measurement is not included to this study.
MAP, mean arterial pressure; NIV, non- invasive ventilation; RRT, renal replacement therapy; SOFA, sequential organ failure assessment.
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90% power and 5% alpha, the study requires 896 patients 
to show the difference. We estimate that 5% of patients 
randomised to native CT group will undergo intravenous 
contrast CT (cross- over from native CT to intravenous 
contrast CT group). Taking this into account, the final 
adjusted sample size will be 994.
Follow-up and data collection
The data and outcomes are recorded prospectively during 
the hospital stay using case report forms and electronic 
patient records. If patients are discharged before 72 hours 
from the CT scan, they will be scheduled for a laboratory 
creatinine control on the third day after the CT scan. 
Patients will be contacted on day 90, either at an outpa-
tient visit or by telephone or mail. If a patient is transferred 
to another hospital during the 90- day period, electronic 
patient records are requested from that hospital, and 
outcomes are assessed using these records. In case no 
contact can be made or patient records are unavailable, 
the primary outcome can further be assessed using (1) 
Statistics Finland death registry (up to date registry for 
mortality), and (2) Finnish Registry for Kidney Diseases 
(up to date registry for permanent RRT). Follow- up data 
on tertiary outcomes at 6 months and 1, 5 and 10 years 
will be similarly assessed using these registries, and also 
from Transplantation Registry for renal transplantation.
Statistical analysis plan
This is a superiority trial. The analyses will be done in the 
intention- to- treat population. The null hypothesis for the 
primary and secondary outcomes is that there is no differ-
ence between the treatment arms. P value of less than 
0.05 will be considered statistically significant and all anal-
yses will be done two- tailed. The primary analyses will be 
performed using stratification variables (age <65 or ≥65 
years, eGFR of 15 to <30 or 30 to ≤45 mL/min/1.73 m2, 
and centre). Additionally, the crude outcomes will be 
reported.
The primary outcome will be analysed using logistic 
regression adjusted for the stratification variables. The 
effect size will be reported using risk ratio corrected from 
OR20 with 95% CI.
The first and second secondary outcomes (AKI, any 
organ failure with mSOFA 2 or more) will be analysed 
using logistic regression adjusted for the stratification 
variables.
The third and fourth secondary outcomes (hospital 
free days, time to definitive treatment) will be analysed 
by using adjusted regression analysis where stratification 
variables are used as covariates.
Tertiary outcomes will be analysed when follow- up data 
for 6 months, 1, 5, and 10 years after CT are available, and 
will be reported using Kaplan- Meier curves with log- rank 
tests.
Prespecified subgroup analyses are defined by: (1) age 
(<65 or ≥65 years), (2) eGFR values (15 to <30 or 30 to 45 
mL/min/1.73 m2), (3) diabetes and (4) ongoing regular 
use of nephrotoxic medications preadmission (ACE 
(angiotensin- converting enzyme) inhibitors, AR (angio-
tensin II receptor) blockers, antimicrobial medications 
(aminoglycosides, cephalosporins, colistin, quinolones, 
rifampicin, sulfamethoxalone/trimethoprim and vanco-
mycin) loop and thiazide diuretics, NSAIDs (non- steroidal 
anti- inflammatory drugs), COX-2 (cyclo- oxygenase-2) 
inhibitors, immunosuppressants and chemotherapy).
Schedule
Approximately 1100 (abdominal or whole body) emer-
gent CT examinations without IV contrast media are 
performed in Helsinki University Hospital’s Meilahti 
Hospital annually. We estimate that one- third could be 
recruited, meaning that approximately 300 patients 
could be recruited annually in Meilahti Hospital alone. 
Depending on the number of hospitals participating in 
the trial, we estimate the patient recruitment to take a 
maximum of 3 years. The estimated start of recruitment 
is autumn 2020.
Patient and public involvement
Patients were not involved in the design of the study or 
assessment of the burden of the interventions. On recruit-
ment, patients are informed of the current knowledge on 
intravenous contrast administration during CT. The risks 
and benefits of the trial intervention are explained to the 
patients.
ETHICS AND DISSEMINATION
This study is approved by The Ethics Committee of 
Helsinki University Hospital. The study data validity and 
quality will be analysed by study monitoring personnel of 
Clinical Research Institute of Helsinki University Central 
Hospital.
All patients will sign a written informed consent after 
receiving oral and written information on the study. Study 
patients do not gain any financial benefit from partici-
pating in the study. They can cancel their participation at 
any time. In these cases, the information gathered before 
the cancellation will be used in the study.
PC- AKI has been a significant concern in patients 
with compromised renal function undergoing contrast 
enhanced CT imaging. Intravenous contrast improves 
image quality. Avoiding contrast administration may 
negatively impact patients’ prognoses by leading to repet-
itive imaging that increases patients’ total radiation load 
and delays diagnosis and treatment. Currently, the limit 
for more liberal intravenous contrast medium use is an 
eGFR level of 45 mL/min/1.73 m2. However, growing 
amount of retrospective data suggests that the intrave-
nous contrast administration is equally safe with lower 
eGFR levels. Randomised trials are necessary to confirm 
these findings.
Outside the study protocol, in participating centres, the 
standard imaging usually includes native CT for patients 
with GFR below 30 mL/min/1.73 m2 and contrast- 
enhanced CT for patients with GFR between 30 to 45 mL/
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min/1.73 m2. Despite this, wide physician- specific varia-
tion in the decision between native or contrast- enhanced 
CT exists, and outside trials, this decision is up to the 
attending physician to make. A study patient randomised 
to the intravenous contrast group may have a slightly 
elevated risk of acute renal injury, but may gain more 
accurate imaging and prompt diagnostics, and possibly 
avoid repeated CT scans with extra radiation. On the 
contrary, a patient randomised to the native CT group 
could have a reduced risk of adverse renal events.
There are possible limitations regarding this study. First, 
the eGFR value is designed to measure kidney function 
in steady state which can be altered dramatically during 
the illness. To take this into account, the baseline creat-
inine value (the last creatinine value before the disease 
onset) will be recorded if available. Second, although this 
is a randomised trial, there are multiple confounders that 
cannot be standardised between the treatment groups. 
These include the post- CT hydration during the first 
3 days after the randomisation as this is tailored based on 
the condition and diagnosis of the patient. Third, while 
the patient recruiting process is made as clear as possible, 
there is a risk for drop- out of patients. Especially patients 
who cannot sign the written consent or whose disease 
process mandates immediate CT imaging may not be 
recruited in the study.
To our knowledge, this is the first randomised controlled 
trial examining the association between intravenous 
contrast administration and patient outcomes. Safety 
interim analyses will be performed after the recruitment 
of 100 patients and at the halfway of recruitment. Interim 
analyses will consist of primary outcome, and secondary 
outcomes 1 to 3. The study can be prematurely stopped 
also for slow recruitment at researchers’ discretion.
The study results will be published in peer- reviewed 
academic journals. The study protocol and results may be 
further disseminated via scientific conferences and social 
media platforms.
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